3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
5
Other hematologic neoplasm
4
CNS
4
Tumor-Agnostic
3
Lymphoid
3
Genitourinary
3
Gastrointestinal
3
Sarcoma
2
Plasma cell
2
Head & Neck
2
Gynecologic
2
Dermatologic
2
Thoracic
1
Other solid neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Classical hematology
1
Conditions
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Interventions
Everolimus
32
Octreotide
15
Cisplatin
14
pasireotide
13
Sunitinib
13
Temozolomide
11
pembrolizumab
10
Etoposide
10
Doxorubicin
10
lanreotide
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
9
lutetium Lu 177 dotatate
8
gallium Ga 68 dotatate
8
Sorafenib
8
Paclitaxel
8
3-Iodobenzylguanidine
8
lenvatinib
7
pazopanib
6
Radiotherapy
6
Positron Emission Tomography Computed Tomography
6
Nivolumab
6
surufatinib
5
cabozantinib
5
avelumab
5
Thyrotropin Alfa
5
Surgical Procedures, Operative
5
Radiosurgery
5
Mitotane
5
Irinotecan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Quality of Life
×
Endocrine
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled